Lumosa Therapeutics Co., Ltd. (TPEX: 6535)

Market Cap	32.40B
Revenue (ttm)	37.82M
Net Income (ttm)	-388.80M
Shares Out	164.90M
EPS (ttm)	-2.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250,496
Open	191.00
Previous Close	191.00
Day's Range	191.00 - 196.50
52-Week Range	66.80 - 400.00
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 4, 2025

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 47
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6535

Financial Performance

In 2023, Lumosa Therapeutics's revenue was 56.92 million, an increase of 113.63% compared to the previous year's 26.64 million. Losses were -238.04 million, -51.88% less than in 2022.